TY  - JOUR
AU  - Galldiks, Norbert
AU  - Werner, Jan-Michael
AU  - Tscherpel, Caroline
AU  - Fink, Gereon R
AU  - Langen, Karl-Josef
TI  - Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI
JO  - Neuro-oncology advances
VL  - 1
IS  - 1
SN  - 2632-2498
CY  - Oxford
PB  - Oxford University Press
M1  - FZJ-2020-01691
SP  - vdz038
PY  - 2019
AB  - The prospective REGOMA phase 2 trial showed an encouraging and significant median progression-free and overall survival (PFS, OS) benefit for glioblastoma patients at first progression treated with the oral multikinase inhibitor regorafenib compared to lomustine monotherapy.1 In particular, the OS benefit was 1.8 months compared to lomustine (7.4 vs. 5.6 months; P = .0009), and the hazard ratio was 0.5 (95% confidence interval, 0.33–0.75). Interestingly, despite unchanged MRI findings at first follow-up (“Stable Disease,” 39%) following regorafenib, complete or partial radiological responses according to the RANO criteria2 were only seen in 5% of cases treated with regorafenib. On the other hand, 59% of patients in the regorafenib arm had grade 3–4 adverse events.
LB  - PUB:(DE-HGF)16
C6  - pmid:32642667
UR  - <Go to ISI:>//WOS:000886002700031
DO  - DOI:10.1093/noajnl/vdz038
UR  - https://juser.fz-juelich.de/record/874903
ER  -